Ochromycinone (STA-21)

Catalog No.S7951 Batch:S795103

Print

Technical Data

Formula

C19H14O4
Molecular Weight 306.31 CAS No. 111540-00-2
Solubility (25°C)* In vitro DMSO 24 mg/mL (78.35 mM)
Ethanol 5 mg/mL (16.32 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ochromycinone (STA-21) is a selective STAT3 inhibitor.
Targets
STAT3 [1]
In vitro Ochromycinone (STA-21) inhibits Stat3 DNA binding activity, Stat3 dimerization, and Stat3-dependent luciferase activity in cells. It remarkably inhibits the growth and the survival of the breast carcinoma cells MDA-MB-231, MDA-MB-435s, and MDA-MB-468 that express persistently activated Stat3. In RH30 and RD2 cells, this compound also inhibits cell viability and growth and induced apoptosis through caspases 3, 8 and 9 pathways.
In vivo In IL-1Ra–KO mice, Ochromycinone (STA-21) (0.5 mg/kg, i.p.) reduces the arthritis score and the incidence of arthritis by decreasing the proportion of Th17 cells and increasing the proportion of Treg cells expressing FoxP3.

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB-468, MCF7, and Caov-3 cells

  • Concentrations

    20 or 30 μM

  • Incubation Time

    48 h

  • Method

    Human breast cancer cell lines MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB-468, and MCF7, human ovarian carcinoma cell line Caov-3, and human skin fibroblasts were cultured in DMEM containing 10% FBS and appropriate antibiotics in a 5% CO2 incubator at 37°C. For testing Ochromycinone (STA-21) and other compounds, the cells were exposed to it for 48 h at a final concentration of 20 or 30 μM, respectively. Then, the cells were harvested and subjected to flow-cytometry analysis.
Animal Study:[3]
  • Animal Models

    IL-1Ra–KO mice

  • Dosages

    0.5 mg/kg

  • Administration

    i.p.

References

  • https://pubmed.ncbi.nlm.nih.gov/15781862/
  • https://pubmed.ncbi.nlm.nih.gov/17598902/
  • https://pubmed.ncbi.nlm.nih.gov/24757144/

Selleck's Ochromycinone (STA-21) Has Been Cited by 17 Publications

Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells [ Cancer Genomics & Proteomics, September 2020, 517-527] PubMed: 32859630
Microglial depletion impairs glial scar formation and aggravates inflammation partly by inhibiting STAT3 phosphorylation in astrocytes after spinal cord injury [ Neural Regeneration Research, June 2023, 1325-1331] PubMed: 36453419
Cationic amphiphilic antihistamines inhibit STAT3 via Ca2+-dependent lysosomal H+ efflux [ Cell Rep, 2023, 42(2):112137] PubMed: 36807142
Microglial depletion impairs glial scar formation and aggravates inflammation partly by inhibiting STAT3 phosphorylation in astrocytes after spinal cord injury [ Neural Regen Res, 2023, 18(6):1325-1331] PubMed: 36453419
Microglial depletion impairs glial scar formation and aggravates inflammation partly by inhibiting STAT3 phosphorylation in astrocytes after spinal cord injury [ Neural Regeneration Research, 2023, 1325-1331] PubMed: 36453419
Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis [ American Journal of Physiology-Lung Cellular and Molecular Physiology, 2022 Dec 1, L698-L714] PubMed: 36283961
Noncanonical JAK1/STAT3 interactions with TGF-β modulate myofibroblast transdifferentiation and fibrosis [ American Journal of Physiology-Lung Cellular and Molecular Physiology, 2022, L698-L714] PubMed: 36283961
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain [ Biochemical Pharmacology, 2021, 114688] PubMed: 34864607
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain [ Biochem Pharmacol, 2021, 192:114688] PubMed: 34274354
Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells [ Cancer Genomics & Proteomics, 2020 Sep, 517-527] PubMed: 32859630

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.